Exane BNP Paribas analyst Richard Parkes upgraded Novo Nordisk (NVO) to Outperform from Neutral with a DKK 930 price target The firm believes 2025 will be a major year for pipeline catalysts and sees potential for a strong sector rally in the European pharma space.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVO:
- RBC sees little cause for concern over CMS’ proposed part D GLP-1 coverage rule
- Trump threatens tariffs, Zoom reports Q3 beat: Morning Buzz
- Amgen (NASDAQ:AMGN) Sinks despite Positive MariTide Trial Data
- Novo Nordisk Stock Jumps on Biden Weight Loss Proposal Despite Upcoming Trump Presidency
- Weight loss drugmakers in spotlight as White House proposes coverage